Reassessing mid-term risks
06/07/26 -"Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due to the impending patent expiry of Ipsen's ..."
Pages
52
Language
English
Published on
06/07/26
You may also be interested by these reports :
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...
06/07/26
Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due ...
30/06/26
The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...
24/06/26
Rather than trying to figure out who will win the obesity race, why not bet on more defensive upstream API production?